ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 36.13% | 34.60% | 22.34% | 13.58% | 7.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 36.13% | 34.60% | 22.34% | 13.58% | 7.58% |
| Cost of Revenue | 260.32% | 280.18% | 281.07% | 144.43% | 42.51% |
| Gross Profit | -487.63% | -529.43% | -548.94% | -206.65% | -112.06% |
| SG&A Expenses | 5.75% | 18.90% | 46.99% | 29.67% | 2.87% |
| Depreciation & Amortization | -3.40% | -12.13% | -27.00% | -26.29% | -33.96% |
| Other Operating Expenses | 38.31% | 7.65% | 23.82% | -8.13% | -74.16% |
| Total Operating Expenses | 21.79% | 24.03% | 30.01% | 12.11% | -21.48% |
| Operating Income | -21.48% | -23.82% | -30.18% | -12.09% | 21.93% |
| Income Before Tax | -72.76% | -53.04% | -90.80% | -89.18% | 10.49% |
| Income Tax Expenses | -9,702.05% | -10,353.77% | -10,542.82% | -9,410.84% | 20.07% |
| Earnings from Continuing Operations | -49.32% | -32.38% | -67.59% | -66.91% | 10.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.32% | -32.38% | -67.59% | -66.91% | 10.46% |
| EBIT | -21.48% | -23.82% | -30.18% | -12.09% | 21.93% |
| EBITDA | -26.00% | -32.16% | -47.94% | -22.91% | 18.43% |
| EPS Basic | 5.27% | 23.30% | -3.16% | -18.88% | 10.87% |
| Normalized Basic EPS | 45.15% | 51.60% | 35.65% | 19.69% | 9.72% |
| EPS Diluted | 3.93% | 22.22% | -3.96% | -19.23% | 11.44% |
| Normalized Diluted EPS | 45.15% | 51.60% | 35.65% | 19.69% | 9.72% |
| Average Basic Shares Outstanding | 47.39% | 74.51% | 66.39% | 31.83% | 5.09% |
| Average Diluted Shares Outstanding | 47.39% | 74.51% | 66.39% | 31.83% | 5.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
